ACM and PCM according to country of treatment and modified NCCN risk (n=222 163)
| 6-year ACM | Model 1 (age at diagnosis, year of diagnosis, ethnicity, clinical tumour stage and Gleason score) | Model 2 (model 1 and definitive therapy) | ||||
|---|---|---|---|---|---|---|
| Risk group | USA | England | Adj HR (95% CI) | p Value | Adj HR (95% CI) | p Value |
| n=196 928 | n=25 235 | |||||
| All risk groups | 9.3% | 18.5% | 1.60 (1.52 to 1.68) | <0.001 | 1.03 (0.97 to 1.08) | 0.336 |
| Low risk | 8.7% | 10.3% | 1.30 (1.15 to 1.48) | <0.001 | 1.06 (0.93 to 1.21) | 0.397 |
| Intermediate risk | 7.6% | 12.5% | 1.44 (1.32 to 1.58) | <0.001 | 0.98 (0.90 to 1.08) | 0.740 |
| High risk | 16.3% | 31.8% | 1.92 (1.78 to 2.06) | <0.001 | 0.99 (0.92 to 1.08) | 0.863 |
| 6-year PCM | Model 1 (age at diagnosis, year of diagnosis, ethnicity, clinical tumour stage and Gleason score) | Model 2 (model 1 and definitive therapy) | ||||
|---|---|---|---|---|---|---|
| Risk group | USA | England | Adj SHR (95% CI) | p Value | Adj SHR (95% CI) | p Value |
| All risk groups | 2.4% | 7.6% | 1.88 (1.72 to 2.05) | <0.001 | 0.97 (0.88 to 1.07) | 0.568 |
| Low risk | 0.9% | 0.9% | 1.57 (1.08 to 2.30) | 0.018 | 1.31 (0.89 to 1.93) | 0.169 |
| Intermediate risk | 1.4% | 2.8% | 1.71 (1.40 to 2.09) | <0.001 | 1.00 (0.81 to 1.23) | 0.994 |
| High risk | 8.1% | 18.8% | 2.06 (1.87 to 2.28) | <0.001 | 0.96 (0.86 to 1.08) | 0.537 |
ACM, all-cause mortality; Adj HR, adjusted HR; Adj SHR, adjusted subhazard ratios; NCCN, National Comprehensive Cancer Network; PCM, prostate cancer mortality.